New UK Survey Reveals Surprising Insights Into How Airgunners Really Think, Buy and Shoot
Friday 19 December, 2025 A new nationwide survey conducted by The AirGun…
IOC Joins Sport for Refugees Coalition in a Call to Strengthen the Role of Sport in Refugee Responses
12 December 2025 - The International Olympic Committee (IOC) and Olympic Refuge Foundation (ORF)…
Halia Therapeutics to Present Groundbreaking Data on Novel Allosteric NEK7 Inhibitor Ofirnoflast at the 2025 American Society of Hematology Annual Meeting
- Data demonstrates ofirnoflast's efficacy in myelodysplastic syndrome (MDS) with robust and…
Tagvenue Launches Tagvenue PRO, Bringing AI to Help Venues Win More Bookings
Tagvenue has launched Tagvenue PRO, an AI-powered platform that simplifies venue management…
Constellation Software Inc. Announces Release Date for Third Quarter Results
October 20, 2025 17:12 ET | Source: Constellation Software Inc. TORONTO, Oct.…
Subcutaneous RYBREVANT(amivantamab) delivers promising 45 percent overall response rate with median duration of response of 7.2 months in recurrent or metastatic head and neck cancer
Responses were rapid and durable, and tumour shrinkage was observed in 82…
Genmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer
Media Release COPENHAGEN, Denmark; October 18, 2025 Updated data from the Phase…
SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology
BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH),…
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
September 20, 2025 11:00 ET | Source: C4 Therapeutics, Inc. Cemsidomide in…
Scancell reports Phase 2 data showing strongly improved outcomes in Late-Stage Melanoma with its Immunobody iSCIB1+
July 22, 2025 02:00 ET | Source: Scancell Holdings Plc SCOPE trial…